
## David B Clifford

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/344162/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology, 2010, 75, 2087-2096.	1.1	2,036
2	HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of NeuroVirology, 2011, 17, 3-16.	2.1	1,327
3	Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System. Archives of Neurology, 2008, 65, 65.	4.5	777
4	Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy. New England Journal of Medicine, 2006, 354, 924-933.	27.0	744
5	Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurology, The, 2010, 9, 438-446.	10.2	604
6	PML diagnostic criteria. Neurology, 2013, 80, 1430-1438.	1.1	574
7	HIV-associated neurocognitive disorder. Lancet Infectious Diseases, The, 2013, 13, 976-986.	9.1	501
8	Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids, 2004, 18, 2391-400.	2.2	429
9	Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virus–Associated Sensory Neuropathy in the Era of Combination Antiretroviral Therapy. Archives of Neurology, 2010, 67, 552.	4.5	347
10	Failure of Cytarabine in Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1998, 338, 1345-1351.	27.0	343
11	The functional anatomy and pathology of lithium-pilocarpine and high-dose pilocarpine seizures. Neuroscience, 1987, 23, 953-968.	2.3	336
12	Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurology, The, 2007, 6, 431-441.	10.2	331
13	Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study. Clinical Infectious Diseases, 2015, 60, 473-480.	5.8	326
14	Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology, 2014, 82, 2055-2062.	1.1	255
15	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, The, 2011, 10, 745-758.	10.2	247
16	Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. JAMA Neurology, 2018, 75, 1546.	9.0	247
17	HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology, 1999, 52, 623-623.	1.1	245
18	Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis. Archives of Neurology, 2011, 68, 1156.	4.5	244

#	Article	IF	CITATIONS
19	BK Virus: A Clinical Review. Clinical Infectious Diseases, 2001, 33, 191-202.	5.8	237
20	Pharmacogenetics of Longâ€Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study. Journal of Infectious Diseases, 2005, 192, 1931-1942.	4.0	232
21	The DIANâ€TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimer's and Dementia, 2017, 13, 8-19.	0.8	230
22	Inhibition of long-term potentiation by NMDA-mediated nitric oxide release. Science, 1992, 257, 1273-1276.	12.6	226
23	Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals. Annals of Internal Medicine, 2005, 143, 714.	3.9	226
24	lmmune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology, 2011, 77, 1061-1067.	1.1	209
25	Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study. Clinical Infectious Diseases, 2006, 42, 401-407.	5.8	208
26	Ketamine, Phencyclidine, and MKâ€801 Protect Against Kainic Acidâ€Induced Seizureâ€Related Brain Damage. Epilepsia, 1990, 31, 382-390.	5.1	201
27	Cytomegalovirus Encephalitis. Annals of Internal Medicine, 1996, 125, 577.	3.9	191
28	Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nature Reviews Neurology, 2010, 6, 667-679.	10.1	191
29	Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab. New England Journal of Medicine, 2009, 361, 1075-1080.	27.0	190
30	Genotyping of Toxoplasma gondii Strains from Immunocompromised Patients Reveals High Prevalence of Type I Strains. Journal of Clinical Microbiology, 2005, 43, 5881-5887.	3.9	185
31	Pregabalin for painful HIV neuropathy. Neurology, 2010, 74, 413-420.	1.1	185
32	Nitric oxide inhibitors attenuate excitotoxicity in rat hippocampal slices. Neuroscience Letters, 1992, 135, 227-230.	2.1	183
33	A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. Aids, 2002, 16, 1791-1797.	2.2	183
34	Pain in Multiple Sclerosis. Archives of Neurology, 1984, 41, 1270-1272.	4.5	182
35	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
36	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases, 2021, 72, e1-e48.	5.8	174

#	Article	IF	CITATIONS
37	Peripheral neuropathy in HIV: prevalence and risk factors. Aids, 2011, 25, 919-928.	2.2	171
38	Tetrahydrocannabinol for tremor in multiple sclerosis. Annals of Neurology, 1983, 13, 669-671.	5.3	170
39	Clinical factors related to brain structure in HIV: the CHARTER study. Journal of NeuroVirology, 2011, 17, 248-57.	2.1	158
40	CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology, 2009, 73, 1982-1987.	1.1	156
41	Determinants of survival in progressive multifocal leukoencephalopathy. Neurology, 2009, 73, 1551-1558.	1.1	154
42	Progressive multifocal leukoencephalopathy in transplant recipients. Annals of Neurology, 2011, 70, 305-322.	5.3	152
43	Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurology, The, 2018, 17, 467-480.	10.2	147
44	Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 505-522.	1.3	143
45	A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. Journal of NeuroVirology, 2013, 19, 351-358.	2.1	138
46	Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. Aids, 1999, 13, 1677-1685.	2.2	131
47	Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. Aids, 2005, 19, 1341-1349.	2.2	129
48	HIV Subtype D Is Associated with Dementia, Compared with Subtype A, in Immunosuppressed Individuals at Risk of Cognitive Impairment in Kampala, Uganda. Clinical Infectious Diseases, 2009, 49, 780-786.	5.8	129
49	Bacterial Brain Abscess. Neurohospitalist, The, 2014, 4, 196-204.	0.8	122
50	Role of CD4 <sup>+</sup> and CD8 <sup>+</sup> T-Cell Responses against JC Virus in the Outcome of Patients with Progressive Multifocal Leukoencephalopathy (PML) and PML with Immune Reconstitution Inflammatory Syndrome. Journal of Virology, 2011, 85, 7256-7263.	3.4	116
51	Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. Journal of NeuroVirology, 2016, 22, 170-178.	2.1	112
52	Level of Cytomegalovirus (CMV) DNA in Cerebrospinal Fluid of Subjects with AIDS and CMV Infection of the Central Nervous System. Journal of Infectious Diseases, 1995, 172, 527-531.	4.0	110
53	Randomized Trial of Central Nervous System–Targeted Antiretrovirals for HIV-Associated Neurocognitive Disorder. Clinical Infectious Diseases, 2014, 58, 1015-1022.	5.8	110
F 4	Natalizumah JAMA Neurology 2013 70 172	0.0	109

Natalizumab. JAMA Neurology, 2013, 70, 172.

9.0 108

#	Article	IF	CITATIONS
55	Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. American Journal of Neuroradiology, 1999, 20, 1896-906.	2.4	108
56	Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma. Journal of Clinical Microbiology, 1995, 33, 1580-1583.	3.9	103
57	Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Annals of Neurology, 1999, 45, 816-820.	5.3	102
58	Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s). HIV Clinical Trials, 2009, 10, 343-355.	2.0	100
59	Diagnosing Symptomatic HIV-Associated Neurocognitive Disorders: Self-Report <i>Versus</i> Performance-Based Assessment of Everyday Functioning. Journal of the International Neuropsychological Society, 2012, 18, 79-88.	1.8	99
60	2-Amino-3-phosphonopropionate blocks the induction and maintenance of long-term potentiation in rat hippocampal slices. Neuroscience Letters, 1991, 122, 187-190.	2.1	90
61	Notes Progressive Multifocal Leukoencephalopathy in Patients with AIDS Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 1999, 28, 1152-1154.	5.8	88
62	Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. Journal of Antimicrobial Chemotherapy, 2011, 66, 354-357.	3.0	82
63	A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-Associated Distal Sensory Polyneuropathy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 126-133.	2.1	82
64	HIV DNA Reservoir Increases Risk for Cognitive Disorders in cART-NaÃ⁻ve Patients. PLoS ONE, 2013, 8, e70164.	2.5	82
65	Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. Journal of NeuroVirology, 2015, 21, 637-644.	2.1	80
66	A randomized clinical trial of CPI-1189 for HIV-associated cognitive–motor impairment. Neurology, 2002, 59, 1568-1573.	1.1	77
67	White matter damage, neuroinflammation, and neuronal integrity in HAND. Journal of NeuroVirology, 2019, 25, 32-41.	2.1	77
68	Lifetime suicidal ideation and attempt are common among HIV+ individuals. Journal of Affective Disorders, 2012, 136, 993-999.	4.1	75
69	<sup>11</sup> C-PiB Imaging of Human Immunodeficiency Virus–Associated Neurocognitive Disorder. Archives of Neurology, 2012, 69, 72.	4.5	72
70	Nicotinic acetylcholine currents in cultured postnatal rat hippocampal neurons. Molecular Pharmacology, 1992, 41, 931-6.	2.3	72
71	Blockade of desensitization augments quisqualate excitotoxicity in hippocampal neurons. Neuron, 1990, 5, 61-66.	8.1	67
72	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clinical Infectious Diseases, 2021, 72, 1-8.	5.8	66

#	Article	IF	CITATIONS
73	The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. Aids, 2005, 19, S64-S71.	2.2	65
74	Clinical validation of the NeuroScreen. Journal of NeuroVirology, 2005, 11, 503-511.	2.1	65
75	CNS–Immune Reconstitution Inflammatory Syndrome in the Setting of HIV Infection, Part 1: Overview and Discussion of Progressive Multifocal Leukoencephalopathy–Immune Reconstitution Inflammatory Syndrome and Cryptococcal–Immune Reconstitution Inflammatory Syndrome. American Journal of Neuroradiology. 2013. 34. 1297-1307.	2.4	65
76	Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1. Antimicrobial Agents and Chemotherapy, 2010, 54, 5156-5160.	3.2	63
77	HIV-associated neurocognitive disorder. Current Opinion in Infectious Diseases, 2017, 30, 117-122.	3.1	62
78	Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 59-62.	3.0	61
79	Calcium influx through channels activates a potassium current in postnatal rat hippocampal neurons. Neuroscience Letters, 1989, 99, 293-299.	2.1	59
80	Frequency and Phenotype of JC Virus-Specific CD8 + T Lymphocytes in the Peripheral Blood of Patients with Progressive Multifocal Leukoencephalopathy. Journal of Virology, 2007, 81, 3361-3368.	3.4	59
81	Factors Associated With the Onset and Persistence of Post–Lumbar Puncture Headache. JAMA Neurology, 2015, 72, 325.	9.0	59
82	Low concentrations of inhibit the induction of long-term potentiation in rat hippocampal slices. Neuroscience Letters, 1992, 137, 245-248.	2.1	57
83	Long-term potentiation during whole-cell recording in rat hippocampal slices. Neuroscience, 1993, 53, 39-47.	2.3	57
84	Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2013, 19, 150-156.	2.1	57
85	Human Immunodeficiency Virus–Associated Dementia. Archives of Neurology, 2000, 57, 321.	4.5	56
86	The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics Journal, 2008, 8, 71-77.	2.0	56
87	The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. Journal of NeuroVirology, 2013, 19, 109-116.	2.1	54
88	HIV-Associated Dementia. Science, 2000, 288, 439d-439.	12.6	54
89	HIV-associated neuromuscular weakness syndrome. Aids, 2004, 18, 1403-1412.	2.2	53
90	Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. Aids, 2006, 20, 1503-1513.	2.2	53

#	Article	IF	CITATIONS
91	Performances on the CogState and Standard Neuropsychological Batteries Among HIV Patients Without Dementia. AIDS and Behavior, 2011, 15, 1902-1909.	2.7	52
92	JC Virus Antibody and Viremia as Predictors of Progressive Multifocal Leukoencephalopathy in Human Immunodeficiency Virus-1–Infected Individuals. Clinical Infectious Diseases, 2011, 53, 711-715.	5.8	52
93	HIV-associated neurocognitive disease continues in the antiretroviral era. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2008, 16, 94-8.	2.9	51
94	HIV-associated cognitive impairment in sub-Saharan Africa—the potential effect of clade diversity. Nature Clinical Practice Neurology, 2007, 3, 436-443.	2.5	49
95	Use of polymerase chain reaction to demonstrate cytomegalovirus DNA in CSF of patients with human immunodeficiency virus infection. Neurology, 1993, 43, 75-75.	1.1	49
96	HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. Aids, 2001, 15, 747-751.	2.2	47
97	HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Current Neurology and Neuroscience Reports, 2008, 8, 455-461.	4.2	47
98	Neurologic Presentations of Sarcoidosis. Neurologic Clinics, 2010, 28, 185-198.	1.8	47
99	Antiepileptic drug selection for people with HIV/AIDS: Evidenceâ€based guidelines from the ILAE and AAN. Epilepsia, 2012, 53, 207-214.	5.1	47
100	Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial. PLOS Clinical Trials, 2007, 2, e13.	3.5	46
101	Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2011, 23, 921-928.	1.2	46
102	Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. Journal of NeuroVirology, 2007, 13, 67-72.	2.1	45
103	Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. Journal of NeuroVirology, 2013, 19, 557-564.	2.1	45
104	White matter lesions and cerebral atrophy on MR images in patients with and without AIDS dementia complex American Journal of Roentgenology, 1993, 161, 177-181.	2.2	44
105	Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy. Aids, 2019, 33, 475-481.	2.2	44
106	NeuroAIDS in Africa. Journal of NeuroVirology, 2010, 16, 189-202.	2.1	42
107	Characterization of quisqualate receptor desensitization in cultured postnatal rat hippocampal neurons. Journal of Neuroscience, 1991, 11, 3430-3441.	3.6	41
108	Health-Related Quality of Life â€~Well-Being' in HIV Distal Neuropathic Pain is More Strongly Associated with Depression Severity than with Pain Intensity. Psychosomatics, 2012, 53, 380-386.	2.5	40

#	Article	IF	CITATIONS
109	Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology, 2015, 84, 241-250.	1.1	40
110	Progressive multifocal leukoencephalopathy treated with nivolumab. Journal of NeuroVirology, 2019, 25, 284-287.	2.1	40
111	CNS–Immune Reconstitution Inflammatory Syndrome in the Setting of HIV Infection, Part 2: Discussion of Neuro–Immune Reconstitution Inflammatory Syndrome with and without Other Pathogens. American Journal of Neuroradiology, 2013, 34, 1308-1318.	2.4	39
112	The Role of Cohort Studies in Drug Development: Clinical Evidence of Antiviral Activity of Serotonin Reuptake Inhibitors and HMG-CoA Reductase Inhibitors in the Central Nervous System. Journal of NeuroImmune Pharmacology, 2007, 2, 120-127.	4.1	38
113	African Mitochondrial DNA Subhaplogroups and Peripheral Neuropathy during Antiretroviral Therapy. Journal of Infectious Diseases, 2010, 201, 1703-1707.	4.0	38
114	Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. Journal of NeuroVirology, 2013, 19, 393-401.	2.1	38
115	Progressive multifocal leukoencephalopathy therapy. Journal of NeuroVirology, 2015, 21, 632-636.	2.1	37
116	A Randomized Trial Evaluating Prosaptideâ,,¢ for HIV-Associated Sensory Neuropathies: Use of an Electronic Diary to Record Neuropathic Pain. PLoS ONE, 2007, 2, e551.	2.5	36
117	CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. Journal of NeuroVirology, 2015, 21, 559-567.	2.1	36
118	The Cerebrospinal Fluid HIV Risk Score for Assessing Central Nervous System Activity in Persons With HIV. American Journal of Epidemiology, 2014, 180, 297-307.	3.4	35
119	Effects of comorbidity burden and age on brain integrity in HIV. Aids, 2019, 33, 1175-1185.	2.2	35
120	Magnetic resonance brain imaging lacks sensitivity for AIDS associated cytomegalovirus encephalitis. Journal of NeuroVirology, 1996, 2, 397-403.	2.1	34
121	Relationship of Medication Management Test-Revised (MMT-R) Performance to Neuropsychological Functioning and Antiretroviral Adherence in Adults with HIV. AIDS and Behavior, 2012, 16, 2286-2296.	2.7	34
122	Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. Journal of Antimicrobial Chemotherapy, 2013, 68, 684-689.	3.0	34
123	The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. AIDS Research and Human Retroviruses, 2016, 32, 636-647.	1.1	34
124	Acute effects of antidepressants on hippocampal seizures. Annals of Neurology, 1985, 18, 692-697.	5.3	31
125	Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. Pain, 2015, 156, 731-739.	4.2	31
126	Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. Journal of Infectious Diseases, 2016, 213, 1065-1073.	4.0	31

#	Article	IF	CITATIONS
127	Osmotic Demyelination Syndrome. Archives of Neurology, 1989, 46, 343.	4.5	30
128	Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. HIV Clinical Trials, 2007, 8, 437-446.	2.0	30
129	Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. Journal of Neuroinflammation, 2017, 14, 72.	7.2	30
130	Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa. Journal of NeuroVirology, 2011, 17, 166-175.	2.1	29
131	Genetic Variation in Iron Metabolism Is Associated with Neuropathic Pain and Pain Severity in HIV-Infected Patients on Antiretroviral Therapy. PLoS ONE, 2014, 9, e103123.	2.5	29
132	Neurological immune reconstitution inflammatory response. Current Opinion in Neurology, 2015, 28, 295-301.	3.6	29
133	Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States. Journal of the International Neuropsychological Society, 2018, 24, 163-175.	1.8	29
134	Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. Journal of the International Neuropsychological Society, 2019, 25, 507-519.	1.8	28
135	Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Clinical Infectious Diseases, 2015, 61, 1476-1484.	5.8	27
136	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Arthritis Care and Research, 2021, 73, 1-9.	3.4	27
137	AIDS and the brain. American Family Physician, 1987, 36, 101-6.	0.1	27
138	AIDS dementia. Medical Clinics of North America, 2002, 86, 537-550.	2.5	26
139	Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals. Journal of NeuroVirology, 2011, 17, 17-25.	2.1	26
140	Lessons from the clinic: A case of natalizumab-associated PML. Neurology, 2011, 76, 574-574.	1.1	26
141	Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. Journal of NeuroVirology, 2016, 22, 479-487.	2.1	26
142	Genomeâ€wide association study of HIVâ€associated neurocognitive disorder (HAND): A CHARTER group study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 413-426.	1.7	26
143	Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection. Molecular Neurobiology, 2019, 56, 3808-3818.	4.0	26
144	Glycine antagonists block the induction of long-term potentiation in CA1 of rat hippocampal slices. Neuroscience Letters, 1990, 112, 251-256.	2.1	25

#	Article	IF	CITATIONS
145	Etravirine in CSF is highly protein bound. Journal of Antimicrobial Chemotherapy, 2013, 68, 1161-1168.	3.0	25
146	Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining "symptomatic―versus "asymptomatic―HAND. Journal of NeuroVirology, 2017, 23, 67	7-78.	25
147	Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Arthritis and Rheumatology, 2021, 73, 12-20.	5.6	25
148	Ototoxicity associated with dideoxycytidine. Lancet, The, 1990, 335, 1106.	13.7	24
149	Nitric oxide inhibitors attenuate ischemic degeneration in the CA1 region of rat hippocampal slices. Neuroscience Letters, 1996, 210, 157-160.	2.1	24
150	Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. Journal of NeuroVirology, 2012, 18, 511-520.	2.1	24
151	Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. Journal of NeuroVirology, 2014, 20, 620-626.	2.1	24
152	Acute Effects of Lithium on Hippocampal Kindled Seizures. Epilepsia, 1985, 26, 689-692.	5.1	23
153	Lithium enhances neuronal muscarinic excitation by presynaptic facilitation. Neuroscience, 1990, 38, 457-468.	2.3	23
154	Experience and Challenges Presented by a Multicenter Crossover Study of Combination Analgesic Therapy for the Treatment of Painful HIV-Associated Polyneuropathies. Pain Medicine, 2013, 14, 1039-1047.	1.9	23
155	Ocular motor abnormalities in human immunodeficiency virus infection. Annals of Neurology, 1991, 30, 130-138.	5.3	22
156	Opportunistic Viral Infections in the Setting of Human Immunodeficiency Virus. Seminars in Neurology, 1999, 19, 185-192.	1.4	22
157	Serial studies of serum interleukin-2 in chronic progressive multiple sclerosis patients: occurrence of â€ <sup>~</sup> bursts' and effect of cyclosporine. Journal of Neuroimmunology, 1990, 28, 9-14.	2.3	21
158	Norepinephrine reverses inhibition of long-term potentiation in rat hippocampal slices. Neuroscience Letters, 1992, 142, 163-166.	2.1	21
159	Wheat germ agglutinin enhances EPSCs in cultured postnatal rat hippocampal neurons by blocking ionotropic quisqualate receptor desensitization. Journal of Neurophysiology, 1992, 68, 1930-1938.	1.8	21
160	Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. Journal of NeuroVirology, 2013, 19, 137-143.	2.1	19
161	Association between brain volumes and HAND in cART-naÃ <sup>-</sup> ve HIV+ individuals from Thailand. Journal of NeuroVirology, 2015, 21, 105-112.	2.1	18
162	Histoplasmoma: Isolated central nervous system infection with Histoplasma capsulatum in a patient with AIDS. Clinical Neurology and Neurosurgery, 2007, 109, 176-181.	1.4	17

#	Article	IF	CITATIONS
163	Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 326-334.	1.3	17
164	Patterns of peripheral neuropathy in ART-naÃ⁻ve patients initiating modern ART regimen. Journal of NeuroVirology, 2015, 21, 210-218.	2.1	17
165	Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration. Neurotherapeutics, 2020, 17, 955-965.	4.4	17
166	HIV peripheral neuropathy progression: protection with glucose-lowering drugs?. Journal of NeuroVirology, 2012, 18, 428-433.	2.1	16
167	JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. Journal of NeuroVirology, 2017, 23, 141-146.	2.1	16
168	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
169	Concanavalin a enhances excitatory synaptic transmission in cultured rat hippocampal neurons. Synapse, 1993, 13, 94-97.	1.2	15
170	Electrophysiological properties of identified postnatal rat hippocampal pyramidal neurons in primary culture. Developmental Brain Research, 1993, 71, 19-26.	1.7	15
171	Simplification of the Research Diagnosis of HIV-Associated Sensory Neuropathy. HIV Clinical Trials, 2008, 9, 434-439.	2.0	15
172	Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. Journal of NeuroVirology, 2012, 18, 81-90.	2.1	15
173	Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV,the, 2019, 6, e456-e462.	4.7	15
174	Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities. Journal of the International Neuropsychological Society, 2020, 26, 147-162.	1.8	15
175	Leukoencephalopathy with calcifications and cysts: Genetic and phenotypic spectrum. American Journal of Medical Genetics, Part A, 2021, 185, 15-25.	1.2	15
176	Natalizumab and PML: a risky business?. Gut, 2008, 57, 1347-1349.	12.1	14
177	Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2012, 56, 1985-1989.	3.2	14
178	Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. Journal of NeuroVirology, 2014, 20, 304-308.	2.1	14
179	Treatment of pain with antidepressants. American Family Physician, 1985, 31, 181-5.	0.1	14
180	α-Substituted thiobutyrolactones potentiate GABA currents in voltage-clamped chick spinal cord neurons. Neuroscience Letters, 1988, 87, 133-138.	2.1	13

#	Article	IF	CITATIONS
181	Effects of fructose-1,6-bisphosphate on morphological and functional neuronal integrity in rat hippocampal slices during energy deprivation. Neuroscience, 2003, 116, 465-475.	2.3	13
182	Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals. Journal of NeuroVirology, 2016, 22, 607-614.	2.1	13
183	Blockade of ionotropic quisqualate receptor desensitization in rat hippocampal neurons by wheatgerm agglutinin and other lectins. Neuroscience, 1993, 52, 35-44.	2.3	12
184	Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. Annals of Clinical and Translational Neurology, 2020, 7, 1166-1173.	3.7	12
185	Herpesvirus Infections and Risk of Parkinson's Disease. Neurodegenerative Diseases, 2020, 20, 97-103.	1.4	12
186	Blockade of ionotropic quisqualate receptor desensitization by wheat germ agglutinin in cultured postnatal rat hippocampal neurons. Journal of Neurophysiology, 1992, 68, 1917-1929.	1.8	11
187	Viral Escape in Cerebrospinal Fluid—An Achilles Heel of HIV Therapy?. Journal of Infectious Diseases, 2010, 202, 1768-1769.	4.0	11
188	Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. Journal of Clinical Virology, 2011, 52, 328-332.	3.1	11
189	Brain morphometric correlates of metabolic variables in HIV: the CHARTER study. Journal of NeuroVirology, 2014, 20, 603-611.	2.1	11
190	Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post–allogeneic hematopoietic stem cell transplant patient. Blood Advances, 2020, 4, 2387-2391.	5.2	11
191	The Evolving Face of Human Immunodeficiency Virus-Related Progressive Multifocal Leukoencephalopathy: Defining a Consensus Terminology. Journal of NeuroVirology, 2003, 9, 88-92.	2.1	11
192	Family History of Dementia Predicts Worse Neuropsychological Functioning Among HIV-Infected Persons. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 316-323.	1.8	10
193	The relationship of CPE to HIV dementia. Neurology, 2014, 83, 109-110.	1.1	10
194	IgG4-Related Disease of the Skull and Skull Base–A Systematic Review and Report of Two Cases. World Neurosurgery, 2021, 150, 179-196.e1.	1.3	10
195	Stable neurological function in subjects treated with 23-dideoxyinosine. Journal of NeuroVirology, 1997, 3, 233-240.	2.1	9
196	Progressive multifocal leukoencephalopathy with extended natalizumab dosing. Neurology: Clinical Practice, 2018, 8, e12-e14.	1.6	9
197	Neurophysiologic effects of folate compounds in hippocampus, in vitro. Brain Research, 1983, 266, 209-216.	2.2	8
198	Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy. Multiple Sclerosis Journal, 2010, 16, 749-753.	3.0	8

#	Article	IF	CITATIONS
199	Effects of bromowillardiine and willardiine on non-N-methyl-D-aspartate receptors in postnatal rat hippocampal neurons. Molecular Pharmacology, 1991, 40, 45-51.	2.3	8
200	Post-acute sensory neurological sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: the COVID-PN observational cohort study. Pain, 2022, 163, 2398-2410.	4.2	8
201	Convulsant γ-butyrolactones block GABA currents in cultured chick spinal cord neurons. Brain Research, 1989, 484, 102-110.	2.2	7
202	Whipple's Disease Masquerades as Dementia With Lewy Bodies. Alzheimer Disease and Associated Disorders, 2015, 29, 85-89.	1.3	7
203	Characterization of Cellular Immune Responses in Thai Individuals With and Without HIV-Associated Neurocognitive Disorders. AIDS Research and Human Retroviruses, 2018, 34, 685-689.	1.1	7
204	Complex responses activated by ibotenate in postnatal rat hippocampal neurons. Brain Research, 1989, 494, 193-197.	2.2	6
205	Central neurologic complications of HIV infection. Current Infectious Disease Reports, 1999, 1, 187-191.	3.0	6
206	Focal brain lesions in people with HIV. Current Treatment Options in Neurology, 1999, 1, 167-172.	1.8	6
207	Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS: Experience With the CNS HIV Antiretroviral Therapy Effects Research ( <i>CHARTER</i> ) Cohort. Journal of HIV/AIDS and Social Services, 2014, 13, 8-25.	0.7	6
208	Seven-Year Experience From the National Institute of Neurological Disorders and Stroke–Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology, 2020, 77, 755.	9.0	6
209	Cohort study protocol to characterize the incidence and severity of neuropathic pain in patients with severe acute respiratory syndrome coronavirus 2 infection. Pain Reports, 2021, 6, e925.	2.7	6
210	The CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T cells, but not CD4 T cells. Journal of Neuroimmunology, 2022, 367, 577860.	2.3	6
211	Challenges for Clinical Trials to Treat Progressive Multifocal Leukoencephalopathy. Journal of NeuroVirology, 2003, 9, 68-72.	2.1	5
212	HIV-associated neuromuscular weakness syndrome in Brazil: report of the two first cases. Arquivos De Neuro-Psiquiatria, 2007, 65, 848-851.	0.8	5
213	A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. Drug Safety, 2018, 41, 807-816.	3.2	5
214	Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy. Neurology, 2021, 97, e156-e165.	1.1	5
215	Neurologic opportunistic infections. Current Opinion in Neurology, 1995, 8, 175-178.	3.6	4
216	NEUROLOGIC COMPLICATIONS OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION. Neurologist, 1998, 4, 54-65.	0.7	4

#	Article	IF	CITATIONS
217	Vicriviroc and Peripheral Neuropathy: Results from AIDS Clinical Trials Group 5211. HIV Clinical Trials, 2010, 11, 51-58.	2.0	4
218	Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls. Neurotherapeutics, 2016, 13, 571-581.	4.4	4
219	A decade of natalizumab and PML: Has there been a tacit transfer of risk acceptance?. Multiple Sclerosis Journal, 2017, 23, 934-936.	3.0	4
220	Hemochromatosis ( <i>HFE</i> ) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2018, 34, 942-949.	1.1	4
221	Lower CSF A? is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Current HIV Research, 2016, 14, 324-330.	0.5	4
222	Tumefactive demyelination in a patient with human immunodeficiency virus. Journal of NeuroVirology, 2013, 19, 265-269.	2.1	3
223	Susac syndrome in a patient with human immunodeficiency virus infection. Journal of NeuroVirology, 2013, 19, 270-273.	2.1	3
224	Nemesis of neglected neurosarcoidosis. Annals of Clinical and Translational Neurology, 2015, 2, 947-948.	3.7	3
225	Paresthesia Predicts Increased Risk of Distal Neuropathic Pain in Older People with HIV-Associated Sensory Polyneuropathy. Pain Medicine, 2021, 22, 1850-1856.	1.9	3
226	Higher iron stores and the HFE 187C>G variant delay onset of peripheral neuropathy during combination antiretroviral therapy. PLoS ONE, 2020, 15, e0239758.	2.5	3
227	Management of Neurologic Opportunistic Disorders in Human Immunodeficiency Virus Infection. Seminars in Neurology, 1992, 12, 28-33.	1.4	2
228	Challenges for clinical trials on progressive multifocal leukoencephalopathy. Journal of NeuroVirology, 2001, 7, 350-352.	2.1	2
229	Progressive multifocal leukoencephalopathy. Neurology, 2018, 90, 255-256.	1.1	2
230	Checkpoint therapy for progressive multifocal leukoencephalopathy: pointless?. European Journal of Neurology, 2020, 27, 2114-2116.	3.3	2
231	Is successful HIV therapy a Pyrrhic victory for the brain?. Journal of Clinical Investigation, 2019, 129, 3052-3053.	8.2	2
232	Seizures and pregnancy. American Family Physician, 1984, 29, 271-5.	0.1	2
233	Thymectomy in multiple sclerosis. Two preliminary trials. Journal of Thoracic and Cardiovascular Surgery, 1983, 85, 88-93.	0.8	2
234	High alert!. Multiple Sclerosis Journal, 2019, 25, 1685-1685.	3.0	1

#	Article	IF	CITATIONS
235	IGG4-Related Disease in the Skull Base and Calvarium: A Systematic Review and Presentation of Two Cases. , 2021, 82, .		1
236	Progressive Multifocal Leukoencephalopathy in the Era of HAART. , 0, , 375-382.		1
237	Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus. Brain, 2022, 145, 2206-2213.	7.6	1
238	Hyponatremia and the brain. American Family Physician, 1988, 38, 119-24.	0.1	1
239	PML: underdiagnosed in MS patients on natalizumab – Authors' reply. Lancet Neurology, The, 2010, 9, 564-565.	10.2	0
240	Neuroinfectious disease. Neurology: Clinical Practice, 2014, 4, 187-189.	1.6	0
241	FTS-03-03: THE DIAN-TU. , 2014, 10, P247-P247.		0
242	Reply to Haddow, et al Clinical Infectious Diseases, 2015, 60, 1442-3.	5.8	0
243	F4â€03â€02: The Dominantly Inherited Alzheimer Network Trials Unit. Alzheimer's and Dementia, 2016, 12, P326.	0.8	0
244	[ICâ€Pâ€057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.8	0
245	[O1–02–04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
246	Dosing interval of natalizumab in MS. Neurology, 2019, 93, 655-656.	1.1	0
247	Thinking About Getting Older With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2020, 70, 2649-2651.	5.8	0
248	Imaging Synaptic Architecture in Human Immunodeficiency Virus: Checkpoint for Brain Function?. Clinical Infectious Diseases, 2021, 73, 1412-1413.	5.8	0
249	Hope for progressive multifocal leukoencephalopathy. Lancet Neurology, The, 2021, 20, 589-591.	10.2	0
250	The devil's details: pathological correlates of progressive multifocal leukoencephalopathy magnetic resonance imaging. European Journal of Neurology, 2021, , .	3.3	0
251	Neurological aspects of AIDS. Missouri Medicine, 1990, 87, 141-4.	0.3	0